March 10, 2020 / 12:37 PM / 21 days ago

BRIEF-Catabasis Pharmaceuticals Reports Q4 Loss Per Share $0.55

March 10 (Reuters) - Catabasis Pharmaceuticals Inc:

* CATABASIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS

* Q4 LOSS PER SHARE $0.55

* CATABASIS PHARMACEUTICALS - AS OF DEC 31, 2019, CATABASIS HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $36.2 MILLION

* CATABASIS PHARMACEUTICALS - EXPECTS THAT IT HAS SUFFICIENT CASH TO FUND OPERATIONS THROUGH POTENTIAL NDA FILING AND INTO Q3 2021

* EDASALONEXENT GLOBAL PHASE 3 POLARISDMD TRIAL IN DUCHENNE MUSCULAR DYSTROPHY TOP-LINE RESULTS EXPECTED IN Q4 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below